Benchmark Comments On Columbia Laboratories Pregnant Study Results

According to Benchmark, Columbia Laboratories CBRX favorable results in pregnant study were published in the journal Ultrasound in Obstetrics and Gynecology. Benchmark reported that data shows treatment with Columbia's Prochieve reduced incidence of preterm birth 45% compared with placebo (p=0.020). “Prochieve demonstrated statistically significant improvement in three key areas of infant outcomes. Respiratory distress syndrome declined 61% (p=0.03), neonatal morbidity or mortality declined 43% (p=0.04) and the percentage of low birth weight babies declined 53% (p=0.01). These very clinically meaningful results were achieved with no elevation in treatment-related adverse events. We believe these results support marketing clearance at approximately the end of 2011 and should support shares in the interim.” Columbia Laboratories closed yesterday at $3.97.